

Flora Zagouri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1030780/publications.pdf>

Version: 2024-02-01

286
papers

4,363
citations

126907

33
h-index

189892

50
g-index

297
all docs

297
docs citations

297
times ranked

6396
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. <i>Breast Care</i> , 2022, 17, 63-70.	1.4	6
2	Adjuvant Treatment of Elderly Breast Cancer Patients: Offer the Best Chances of Cure. <i>Breast Care</i> , 2022, 17, 71-80.	1.4	2
3	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.	3.9	7
4	High-throughput Proteomic Profiling of Male Breast Cancer Tissue. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 229-240.	2.0	2
5	Molecular testing for prostate cancer in Greek patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 170-170.	1.6	0
6	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. <i>Annals of Oncology</i> , 2022, 33, 616-627.	1.2	44
7	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. <i>Frontiers in Oncology</i> , 2022, 12, 847917.	2.8	12
8	Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors. <i>Cancers</i> , 2022, 14, 1892.	3.7	12
9	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100953.	0.6	1
10	“The emerging role of capivasertib in breast cancer” <i>Breast</i> , 2022, 63, 157-167.	2.2	20
11	Advances in Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6152.	4.1	1
12	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. <i>British Journal of Cancer</i> , 2022, 127, 695-703.	6.4	2
13	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2796.	3.7	9
14	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1118-TPS1118.	1.6	2
15	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e212-e219.	2.4	39
16	The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review. <i>Breast Care</i> , 2021, 16, 6-15.	1.4	13
17	Clinical perspectives of BET inhibition in ovarian cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 237-249.	4.4	23
18	TP53 mutations determined by targeted NGS in breast cancer: a case-control study. <i>Oncotarget</i> , 2021, 12, 2206-2214.	1.8	7

#	ARTICLE	IF	CITATIONS
19	How we treat endocrine complications of immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100011.	4.5	32
20	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	3.7	3
21	Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	2.0	4
22	Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 638895.	2.4	6
23	Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting. <i>Current Oncology</i> , 2021, 28, 1143-1152.	2.2	2
24	Cardiovascular toxicity of breast cancer treatment: an update. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 15-24.	2.3	7
25	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.4	8
26	Trastuzumab administration during pregnancy: an update. <i>BMC Cancer</i> , 2021, 21, 463.	2.6	17
27	Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer. <i>Breast</i> , 2021, 56, S23-S24.	2.2	2
28	Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14558-e14558.	1.6	0
29	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 86.	17.0	31
30	Germline mutations in a clinic-based series of pregnancy associated breast cancer patients. <i>BMC Cancer</i> , 2021, 21, 572.	2.6	9
31	Safety outcomes from monarchE: phase 3 study of abemaciclib combined with endocrine therapy (ET) for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer (EBC). <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, .	0.0	0
32	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	0.4	10
33	Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. <i>Frontiers in Oncology</i> , 2021, 11, 683057.	2.8	1
34	CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience. <i>Medical Sciences (Basel)</i> , 2021, 10, 142.	2.9	0
35	MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 4114.	3.7	10
36	Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100826.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Effect Of Exercise On Physical Performance And Quality Of Life In Cancer Patients During Chemotherapy. <i>Medicine and Science in Sports and Exercise</i> , 2021, 53, 473-473.	0.4	0
38	Exercise Training-induced Hormonal And Lean Body Mass Changes In Breast Cancer Patients Undergoing Chemotherapy. <i>Medicine and Science in Sports and Exercise</i> , 2021, 53, 474-474.	0.4	0
39	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	2.4	10
40	Immune checkpoint inhibitor administration during pregnancy: a case series. <i>ESMO Open</i> , 2021, 6, 100262.	4.5	29
41	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	2.2	15
42	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. <i>Cancers</i> , 2021, 13, 465.	3.7	7
43	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NltCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	2.5	12
44	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	1.8	10
45	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	4.4	10
46	Update Overview of the Role of Angiopoietins in Lung Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 1191.	2.0	10
47	Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Ovarian Research</i> , 2021, 14, 148.	3.0	10
48	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. <i>Current Oncology</i> , 2021, 28, 4446-4456.	2.2	2
49	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. <i>Current Oncology</i> , 2021, 28, 4862-4873.	2.2	0
50	Genetic variability of the HPV16 early genes and LCR. Present and future perspectives. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e19.	3.9	10
51	The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 797505.	2.8	4
52	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e36-e53.	2.4	29
53	The learning curve of breast lesion excision system: Balancing patient's safety and surgical training. <i>Breast Journal</i> , 2020, 26, 803-805.	1.0	0
54	GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in a 2 line recurrent or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 160-161.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 1773.	2.8	23
56	Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer. <i>Case Reports in Oncology</i> , 2020, 13, 627-632.	0.7	8
57	Clinical Perspectives of ERCC1 in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8829.	4.1	6
58	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100615.	0.6	7
59	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.	0.9	1
60	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. <i>ESMO Open</i> , 2020, 5, e000774.	4.5	20
61	A Case Series of BCOR Sarcomas With a New Splice Variant of <i>BCOR/CCNB3</i> Fusion Gene. <i>In Vivo</i> , 2020, 34, 2947-2954.	1.3	7
62	The emerging role of BET inhibitors in breast cancer. <i>Breast</i> , 2020, 53, 152-163.	2.2	31
63	Supportive medication in cancer during pregnancy. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 747.	2.4	3
64	318P The real-world Hellenic disease management patterns with everolimus (EVE) for women with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (aBC): â€”The MIRRORâ€™ study. <i>Annals of Oncology</i> , 2020, 31, S370.	1.2	1
65	Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy. <i>Cancers</i> , 2020, 12, 3623.	3.7	10
66	ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 85-96.	2.5	2
67	84P Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials. <i>Annals of Oncology</i> , 2020, 31, S43.	1.2	0
68	First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. <i>Anticancer Research</i> , 2020, 40, 929-938.	1.1	7
69	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanesâ€”a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020, 123, 355-361.	6.4	8
70	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metaanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	7.7	39
71	Axitinib as a third or further line of treatment in renal cancer: a single institution experience. <i>BMC Urology</i> , 2020, 20, 60.	1.4	3
72	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2020, 157, 599-605.	1.4	5

#	ARTICLE	IF	CITATIONS
73	<p>Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising</p>. Therapeutics and Clinical Risk Management, 2020, Volume 16, 141-146.	2.0	2
74	Carotid Disease and Ageing: A Literature Review on the Pathogenesis of Vascular Senescence in Older Subjects. Current Gerontology and Geriatrics Research, 2020, 2020, 1-10.	1.6	9
75	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	2.0	2
76	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunology, Immunotherapy, 2020, 69, 1549-1564.	4.2	19
77	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 2020, 11, 1-14.	1.8	1
78	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. Annals of Translational Medicine, 2020, 8, 1603-1603.	1.7	8
79	Determination of FABP4, RBP4 and the MMP'/NGAL complex in the serum of women with breast cancer. Oncology Letters, 2020, 21, 85.	1.8	9
80	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. Blood, 2020, 136, 8-8.	1.4	0
81	Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. Cancer Treatment Reviews, 2019, 79, 101885.	7.7	13
82	Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting. Annals of Oncology, 2019, 30, v118.	1.2	1
83	Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Annals of Oncology, 2019, 30, 1601-1612.	1.2	146
84	<p>Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study</p>. OncoTargets and Therapy, 2019, Volume 12, 4195-4202.	2.0	2
85	Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. Critical Reviews in Oncology/Hematology, 2019, 140, 80-87.	4.4	3
86	Opposite Prognostic Impact of Single PTEN-loss and<i>PIK3CA</i>Mutations in Early High-risk Breast Cancer. Cancer Genomics and Proteomics, 2019, 16, 195-206.	2.0	13
87	Discrepancies of current recommendations in breast cancer follow-up: a systematic review. Breast Cancer, 2019, 26, 681-686.	2.9	1
88	Serum Proteomic Signatures of Male Breast Cancer. Cancer Genomics and Proteomics, 2019, 16, 129-137.	2.0	22
89	Prognostic significance of miR-34 rs4938723 T&#x2013;C polymorphism in triple negative breast cancer patients. Clinical Biochemistry, 2019, 68, 9-14.	1.9	9
90	Paving the way for changing perceptions in breast surgery: a systematic literature review focused on oncological and aesthetic outcomes of oncoplastic surgery for breast cancer. Breast Cancer, 2019, 26, 416-427.	2.9	13

#	ARTICLE	IF	CITATIONS
91	Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?. ESMO Open, 2019, 4, e000479.	4.5	8
92	P1573Chemotherapy-induced vasotoxicity in patients undergoing therapy for breast cancer. European Heart Journal, 2019, 40, .	2.2	0
93	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. International Journal of Cancer, 2019, 145, 559-568.	5.1	10
94	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International Journal of Clinical Oncology, 2019, 24, 411-419.	2.2	4
95	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Cancer Treatment Reviews, 2019, 73, 54-61.	7.7	28
96	Prognostic role of microRNAs in breast cancer: A systematic review. Oncotarget, 2019, 10, 7156-7178.	1.8	28
97	Clinical and biological implications of Hippo pathway dysregulation in sarcomas. Forum of Clinical Oncology, 2019, 9, 11-16.	0.2	1
98	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Clinical Breast Cancer, 2018, 18, 53-62.e3.	2.4	8
99	Evaluation of chemotherapy response score and lymphocytic infiltration as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. Annals of Oncology, 2018, 29, viii346.	1.2	0
100	Actionable mutations and overall survival in 3,211 patients with cancer: The Hellenic cooperative oncology group precision medicine initiative. Annals of Oncology, 2018, 29, viii664.	1.2	0
101	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. BMC Cancer, 2018, 18, 1247.	2.6	29
102	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Cancer Medicine, 2018, 7, 5066-5082.	2.8	12
103	P1577Cancer therapeutic related vaso- and cardio-toxicity in patients receiving chemotherapy for breast cancer. European Heart Journal, 2018, 39, .	2.2	0
104	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. PLoS ONE, 2018, 13, e0200302.	2.5	21
105	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget, 2018, 9, 36906-36913.	1.8	7
106	Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. Hellenic Journal of Cardiology, 2017, 58, 215-219.	1.0	17
107	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Journal of Translational Medicine, 2017, 15, 30.	4.4	14
108	Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Annals of Oncology, 2017, 28, 1842-1848.	1.2	43

#	ARTICLE	IF	CITATIONS
109	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. <i>Oncologist</i> , 2017, 22, 667-679.	3.7	62
110	Breast lymphoma in a patient with B-cell Non Hodgkin Lymphoma: A case report study. <i>International Journal of Surgery Case Reports</i> , 2017, 40, 1-5.	0.6	11
111	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	2.2	37
112	RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e143.	0.4	0
113	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 1707-1714.	1.8	7
114	Flow-Mediated Dilation of Brachial Artery as a Screening Tool for Anthracycline-Induced Cardiotoxicity. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3072.	2.8	8
115	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	3.7	17
116	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. <i>Radiology</i> , 2017, 282, 484-493.	7.3	81
117	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	1.4	21
118	Intrinsic tumor features underlying clinical subtype discordance in early breast cancer. <i>Annals of Oncology</i> , 2017, 28, v55-v56.	1.2	0
119	Protein expression patterns of cell cycle regulators in operable breast cancer. <i>PLoS ONE</i> , 2017, 12, e0180489.	2.5	14
120	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 2947-2957.	1.1	9
121	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 181-195.	2.0	30
122	The fate of BRCA1-related germline mutations in triple-negative breast tumors. <i>American Journal of Cancer Research</i> , 2017, 7, 98-114.	1.4	4
123	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	1.8	30
124	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	2.5	8
125	Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors. <i>Breast Journal</i> , 2016, 22, 561-563.	1.0	14
126	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	2.5	16

#	ARTICLE	IF	CITATIONS
127	Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2016, 21, 225-237.	2.4	25
128	Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S76-S77.	0.4	0
129	Adding the power of iodinated contrast media to the credibility of mammography in breast cancer diagnosis. British Journal of Radiology, 2016, 89, 20160397.	2.2	19
130	Cancer in pregnancy: disentangling treatment modalities. ESMO Open, 2016, 1, e000016.	4.5	51
131	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Annals of Oncology, 2016, 27, 1733-1739.	1.2	28
132	Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors. Cutaneous and Ocular Toxicology, 2016, 35, 13-20.	1.3	11
133	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1776-1780.	1.3	3
134	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS ONE, 2016, 11, e0164013.	2.5	4
135	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget, 2016, 7, 5074-5087.	1.8	54
136	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. Blood, 2016, 128, 4488-4488.	1.4	0
137	Disease evolution and heterogeneity in bilateral breast cancer. American Journal of Cancer Research, 2016, 6, 2611-2630.	1.4	5
138	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. Anticancer Research, 2016, 36, 2365-78.	1.1	6
139	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. Journal of Translational Medicine, 2015, 13, 171.	4.4	15
140	Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing. Hereditary Cancer in Clinical Practice, 2015, 13, 17.	1.5	2
141	Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. OncoTargets and Therapy, 2015, 8, 2187.	2.0	11
142	Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?. OncoTargets and Therapy, 2015, 8, 1843.	2.0	5
143	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS ONE, 2015, 10, e0140293.	2.5	29
144	Pseudomamma of the inguinal region in a female patient: A case report. International Journal of Surgery Case Reports, 2015, 12, 71-74.	0.6	4

#	ARTICLE	IF	CITATIONS
145	An update on the use of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2015, 16, 1865-1877.	1.8	9
146	Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Research and Treatment, 2015, 149, 269-275.	2.5	34
147	Aromatase inhibitors in male breast cancer: a pooled analysis. Breast Cancer Research and Treatment, 2015, 151, 141-147.	2.5	31
148	Discrepancies between ESMO and NCCN breast cancer guidelines: An Appraisal. Breast, 2015, 24, 513-523.	2.2	26
149	Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 563-577.e3.	0.4	50
150	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Critical Reviews in Oncology/Hematology, 2015, 93, 36-49.	4.4	18
151	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. Blood, 2015, 126, 4178-4178.	1.4	12
152	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. Blood, 2015, 126, 3045-3045.	1.4	0
153	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. Blood, 2015, 126, 1074-1074.	1.4	0
154	Immunohistochemical expression of sex steroid hormone receptors, cell cycle regulators and angiogenesis factors in intraductal papillary mucinous neoplasms: an explorative study. Anticancer Research, 2015, 35, 1049-56.	1.1	0
155	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Anticancer Research, 2015, 35, 4023-36.	1.1	8
156	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. Histology and Histopathology, 2015, 30, 1129-41.	0.7	2
157	Investigating the Clinical Relevance of Genomic Characteristics in Luminal a and B Breast Cancer (Bc). Annals of Oncology, 2014, 25, iv87.	1.2	1
158	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leukemia and Lymphoma, 2014, 55, 2018-2023.	1.3	57
159	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care, 2014, 9, 6-6.	1.4	8
160	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. European Journal of Haematology, 2014, 92, 308-312.	2.2	31
161	Cyclin D1, p16 ^{INK4A} and p27 ^{Kip1} in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis. Apmis, 2014, 122, 1230-1239.	2.0	11
162	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast, 2014, 23, 234-243.	2.2	26

#	ARTICLE	IF	CITATIONS
163	VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1331-1337.	1.0	29
164	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 330-338.	2.4	10
165	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.	7.2	57
166	Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. <i>Pharmacogenomics Journal</i> , 2014, 14, 248-255.	2.0	6
167	Gynecologic oncology patients in the surgical high dependency unit: an analysis of indications. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 335-339.	1.7	2
168	The effect of U-74389G on pancreas ischemia-reperfusion injury in a swine model. <i>Journal of Surgical Research</i> , 2014, 187, 450-457.	1.6	10
169	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3461-3461.	1.4	1
170	Female breast cancer in Europe: statistics, diagnosis and treatment modalities. <i>Journal of Thoracic Disease</i> , 2014, 6, 589-90.	1.4	11
171	Low protein expression of MET in ER-positive and HER2-positive breast cancer. <i>Anticancer Research</i> , 2014, 34, 1227-31.	1.1	6
172	Pertuzumab in Breast Cancer: A Systematic Review. <i>Clinical Breast Cancer</i> , 2013, 13, 315-324.	2.4	11
173	Hsp90 inhibitors in breast cancer: A systematic review. <i>Breast</i> , 2013, 22, 569-578.	2.2	59
174	Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 97-102.	1.7	16
175	Taxanes for Breast Cancer During Pregnancy: A Systematic Review. <i>Clinical Breast Cancer</i> , 2013, 13, 16-23.	2.4	56
176	MMP-2 \sim 1306C>T polymorphism in breast cancer: a case-control study in a South European population. <i>Molecular Biology Reports</i> , 2013, 40, 5035-5040.	2.3	9
177	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 13-22.	2.5	114
178	Trastuzumab administration during pregnancy: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 349-357.	2.5	146
179	Beta-Thalassemia Major: Does It Confer Particularities to the Breast?. <i>Breast Journal</i> , 2013, 19, 124-125.	1.0	4
180	High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 1100-1105.	6.4	69

#	ARTICLE	IF	CITATIONS
181	Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>British Journal of Cancer</i> , 2013, 108, 2259-2263.	6.4	48
182	Fulvestrant and male breast cancer: a case series. <i>Annals of Oncology</i> , 2013, 24, 265-266.	1.2	19
183	Molecularly Targeted Therapies in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2013, 42, 760-773.	1.1	26
184	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013, 24, 647-654.	1.2	117
185	Breast Cancer in Women Aged 25 Years and Younger. <i>Obstetrics and Gynecology</i> , 2013, 121, 1235-1240.	2.4	7
186	Platinum Derivatives During Pregnancy in Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 337-343.	2.4	76
187	Does Pregnancy-Associated Breast Cancer Imply a Worse Prognosis? A Matched Case-Case Study. <i>Breast Care</i> , 2013, 8, 203-207.	1.4	27
188	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 1935-1935.	1.4	18
189	Challenges in managing breast cancer during pregnancy. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S62-7.	1.4	12
190	Screening in the Era of Economic Crisis: Misperceptions and Misuse from a Longitudinal Study on Greek Women Undergoing Benign Vacuum-assisted Breast Biopsy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5023-5029.	1.2	3
191	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. <i>Blood</i> , 2013, 122, 1866-1866.	1.4	0
192	Lenalidomide Administration In Patients With POEMS Syndrome. <i>Blood</i> , 2013, 122, 3235-3235.	1.4	1
193	Prophylactic mastectomy: an appraisal. <i>American Surgeon</i> , 2013, 79, 205-12.	0.8	3
194	Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer. <i>Pharmaceuticals</i> , 2012, 5, 1008-1020.	3.8	49
195	Taxanes for Ovarian Cancer during Pregnancy: A Systematic Review. <i>Oncology</i> , 2012, 83, 234-238.	1.9	33
196	mTOR inhibitors in breast cancer: A systematic review. <i>Gynecologic Oncology</i> , 2012, 127, 662-672.	1.4	34
197	Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. <i>International Journal of Cardiology</i> , 2012, 154, 341-344.	1.7	4
198	Merkel cell carcinoma in pelvic lymph nodes after surgical staging for endometrial cancer: A case report and review of the literature. <i>International Journal of Surgery Case Reports</i> , 2012, 3, 340-342.	0.6	3

#	ARTICLE	IF	CITATIONS
199	A Woman with Breast Cancer and Severe Impaired Lactose Tolerance: An Intriguing Therapeutic Dilemma. <i>Breast Journal</i> , 2012, 18, 628-629.	1.0	2
200	Macular oedema due to letrozole: A first case report. <i>Australasian journal of optometry</i> , The, 2012, 95, 646-650.	1.3	10
201	HTERT MNS16A polymorphism in breast cancer: a caseâ€“control study. <i>Molecular Biology Reports</i> , 2012, 39, 10859-10863.	2.3	8
202	HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a caseâ€“control study. <i>Molecular Biology Reports</i> , 2012, 39, 10873-10879.	2.3	36
203	Mucinous Tubular and Spindle Cell Carcinoma of the Kidney:A Case Report. <i>Case Reports in Oncology</i> , 2012, 5, 347-353.	0.7	10
204	Laparoscopic Repair of Giant Paraesophageal Hernia with Synthetic Mesh: 45 Consecutive Cases. <i>American Surgeon</i> , 2012, 78, 432-435.	0.8	6
205	Breast cancer: is there a need for biopsy of metastases?. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 125-128.	0.5	0
206	Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. <i>Breast</i> , 2012, 21, 534-538.	2.2	66
207	Molecularly targeted therapies in cervical cancer. A systematic review. <i>Gynecologic Oncology</i> , 2012, 126, 291-303.	1.4	68
208	Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. <i>Anticancer Research</i> , 2012, 32, 1021-6.	1.1	18
209	Laparoscopic repair of giant paraesophageal hernia with synthetic mesh: 45 consecutive cases. <i>American Surgeon</i> , 2012, 78, 432-5.	0.8	5
210	Neurofibromatosis 1 and breast cancer: be alert. <i>American Surgeon</i> , 2012, 78, E446-7.	0.8	2
211	Dual carcinoma of the breast with neuroendocrine differentiation. <i>American Surgeon</i> , 2012, 78, E457-8.	0.8	0
212	Serum MMPs and TIMPs: May be predictors of breast carcinogenesis?. <i>Clinica Chimica Acta</i> , 2011, 412, 537-540.	1.1	6
213	Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. <i>Cancer Treatment Reviews</i> , 2011, 37, 599-610.	7.7	27
214	Effects of Lazaroids on Intestinal Ischemia and Reperfusion Injury in Experimental Models. <i>Journal of Surgical Research</i> , 2011, 166, 265-274.	1.6	24
215	Cholangiocarcinoma: principles and current trends. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2011, 10, 10-20.	1.3	47
216	Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience. <i>Gynecologic Oncology</i> , 2011, 123, 37-42.	1.4	17

#	ARTICLE	IF	CITATIONS
217	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. American Journal of Hematology, 2011, 86, 882-884.	4.1	16
218	Mucocelelike Lesions and Vacuum-Assisted Breast Biopsy: Advantages and Particularities. American Journal of Roentgenology, 2011, 196, W665-W665.	2.2	1
219	Sarcomas of the Fallopian Tube: Disentangling a Rare Entity. Onkologie, 2011, 34, 132-138.	0.8	8
220	Breast lesions in patients with Mazabraud or McCune-Albright syndrome. American Surgeon, 2011, 77, E7-8.	0.8	0
221	Serum levels of HSP90 in the continuum of breast ductal and lobular lesions. In Vivo, 2011, 25, 669-72.	1.3	6
222	Vacuum-assisted breast biopsy: more cores, more hematomas?. In Vivo, 2011, 25, 703-5.	1.3	13
223	Cutaneous metastasis of signet-ring gastric adenocarcinoma to the breast with unusual clinicopathological features. Anticancer Research, 2011, 31, 2373-8.	1.1	11
224	Tumor dissemination after laparoscopic surgery for an unsuspected endometrial stromal tumor. European Journal of Gynaecological Oncology (discontinued), 2011, 32, 362-3.	0.2	1
225	Breast self-examination and adherence to mammographic follow-up: an intriguing diptych after benign breast biopsy. European Journal of Cancer Prevention, 2010, 19, 71-72.	1.3	6
226	Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer, 2010, 10, 353.	2.6	31
227	Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study. BMC Cancer, 2010, 10, 409.	2.6	12
228	Volume of blood suctioned during vacuum-assisted breast biopsy predicts later hematoma formation. BMC Research Notes, 2010, 3, 70.	1.4	9
229	Comparison of molecular markers expression in vacuum-assisted biopsies and surgical specimens of human breast carcinomas. Pathology Research and Practice, 2010, 206, 30-33.	2.3	4
230	Downgrading BIRADS 3 to BIRADS 2 category using a computer-aided microcalcification analysis and risk assessment system for early breast cancer. Computers in Biology and Medicine, 2010, 40, 853-859.	7.0	7
231	Is antibiotic use a risk factor for breast cancer? A meta-analysis. Pharmacoepidemiology and Drug Safety, 2010, 19, 1101-1107.	1.9	24
232	Prospective Evaluation of Health-Related Quality of Life in a Homogeneous Mediterranean Group of Colorectal Cancer Patients. American Surgeon, 2010, 76, 502-508.	0.8	7
233	Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?. Obstetrics and Gynecology International, 2010, 2010, 1-11.	1.3	40
234	Lobular Breast Cancer in Men: Case Report and Review of the Literature. Oncology Research and Treatment, 2010, 33, 698-700.	1.2	4

#	ARTICLE	IF	CITATIONS
235	Ruptured cystadenoma of a duplicated appendix. <i>American Surgeon</i> , 2010, 76, 341-3.	0.8	2
236	Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2010, 31, 268-77.	0.2	13
237	Acute intermittent porphyria in pregnancy: a common misdiagnosis. <i>Clinical and Experimental Obstetrics and Gynecology</i> , 2010, 37, 256-60.	0.2	6
238	Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease. <i>Onkologie</i> , 2009, 32, 758-761.	0.8	21
239	Biopsy Method: A Major Predictor of Adherence After Benign Breast Biopsy?. <i>American Journal of Roentgenology</i> , 2009, 193, W452-W457.	2.2	5
240	Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. <i>BMC Cancer</i> , 2009, 9, 390.	2.6	90
241	Breast ductal endoscopy: how many procedures qualify?. <i>BMC Research Notes</i> , 2009, 2, 115.	1.4	12
242	Fine-needle aspiration breast biopsy: Analysis of pain. <i>Diagnostic Cytopathology</i> , 2009, 37, 74-75.	1.0	1
243	Sampling lobular neoplasia of the breast: underestimation despite technical success?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 715-716.	2.8	0
244	Increased expression of macrophage inflammatory protein-1 α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. <i>Leukemia</i> , 2009, 23, 2177-2181.	7.2	54
245	Ductal Endoscopy of the Breast: More Painful at the Luteal Phase?. <i>Pain Practice</i> , 2009, 9, 221-224.	1.9	4
246	Early Breast Cancer Diagnosis in Europe, 2007: Disastrous Exceptions Exist. <i>Breast Journal</i> , 2009, 15, 101-101.	1.0	0
247	Spider Bite on a Male Breast: A Rare Case in the Capital. <i>Breast Journal</i> , 2009, 15, 208-209.	1.0	1
248	Diagnosis of papillary lesions in breast biopsy: is conservative management justified?. <i>American Journal of Surgery</i> , 2009, 197, 550.	1.8	1
249	Treatment of early uterine sarcomas: disentangling adjuvant modalities. <i>World Journal of Surgical Oncology</i> , 2009, 7, 38.	1.9	35
250	Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 5224.	3.3	17
251	Excisional breast biopsy under local anesthesia: stress-related neuroendocrine, metabolic and immune reactions during the procedure. <i>In Vivo</i> , 2009, 23, 649-52.	1.3	3
252	Management of advanced stage uterine sarcomas: a bone of contention. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2009, 30, 483-92.	0.2	4

#	ARTICLE	IF	CITATIONS
253	Minimizing underestimation rate of microcalcifications excised via vacuum-assisted breast biopsy: a blind study. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 397-402.	2.5	38
254	Lesions of "Uncertain Malignant Potential" Diagnosed by Vacuum-Assisted Breast Biopsy: An Unclear Management?. <i>Annals of Surgical Oncology</i> , 2008, 15, 2053-2054.	1.5	1
255	What parameters affect pain in core biopsy?. <i>European Radiology</i> , 2008, 18, 1144-1145.	4.5	4
256	Cores with microcalcifications in DCIS diagnosis: how many cores make the difference?. <i>European Radiology</i> , 2008, 18, 2398-2398.	4.5	1
257	Evaluation of pain experienced during breast ductal endoscopy. <i>Surgery Today</i> , 2008, 38, 886-889.	1.5	3
258	PREDICTORS OF PAIN DURING OPEN BREAST BIOPSY UNDER LOCAL ANESTHESIA: IS THERE SUCH A THING?. <i>Pain Practice</i> , 2008, 8, 151-151.	1.9	1
259	Imprint cytology of vacuum-assisted breast biopsy specimens: a rapid diagnostic tool in non-palpable solid lesions. <i>Cytopathology</i> , 2008, 19, 311-315.	0.7	1
260	Heat shock protein90 in lobular neoplasia of the breast. <i>BMC Cancer</i> , 2008, 8, 312.	2.6	7
261	Pain in different methods of breast biopsy: Emphasis on vacuum-assisted breast biopsy. <i>Breast</i> , 2008, 17, 71-75.	2.2	40
262	Atypical ductal hyperplasia: A way to minimize underestimation in vacuum-assisted breast biopsy?. <i>Breast</i> , 2008, 17, 6.	2.2	9
263	Pain during vacuum-assisted breast biopsy: Are there any predictors?. <i>Breast</i> , 2008, 17, 592-595.	2.2	6
264	Vacuum-assisted breast biopsy in close proximity to the skin: a case report. <i>Journal of Medical Case Reports</i> , 2008, 2, 165.	0.8	2
265	Vacuum-assisted breast biopsy: an easy-to-learn procedure?. <i>American Journal of Surgery</i> , 2008, 196, 798.	1.8	6
266	Vacuum-assisted breast biopsy: more cores, more scars?. <i>Clinical Radiology</i> , 2008, 63, 736-737.	1.1	6
267	Lesions Too Close to the Chest Wall: A Relative Contraindication for Vacuum-Assisted Breast Biopsy. <i>American Journal of Roentgenology</i> , 2008, 190, W270-W270.	2.2	0
268	Breast Ductal Endoscopy: Do Not Neglect Education. <i>Onkologie</i> , 2008, 31, 136-136.	0.8	11
269	Diagnosing Papillary Lesions Using Vacuum-Assisted Breast Biopsy: Should Conservative or Surgical Management Follow?. <i>Oncology Research and Treatment</i> , 2008, 31, 653-656.	1.2	14
270	Giant Cell Arteritis of the Breast and Breast Cancer: Paraneoplastic Manifestation or Concomitant Disease? A Case Report. <i>Oncology Research and Treatment</i> , 2008, 31, 685-688.	1.2	10

#	ARTICLE	IF	CITATIONS
271	Lobular Neoplasia in Vacuum-Assisted Breast Biopsy: Extended Protocols and Underestimation. American Journal of Roentgenology, 2008, 190, W272-W272.	2.2	3
272	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. Blood, 2008, 112, 1725-1725.	1.4	3
273	Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).. Blood, 2008, 112, 1734-1734.	1.4	1
274	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trepine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2008, 112, 5119-5119.	1.4	0
275	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. Blood, 2008, 112, 1726-1726.	1.4	0
276	Chronic cholecystitis in elderly patients. Correlation of the severity of inflammation with the number and size of the stones. In Vivo, 2008, 22, 269-72.	1.3	5
277	Vacuum-assisted breast biopsy in nonpalpable solid breast lesions without microcalcifications: the Greek experience. Diagnostic and Interventional Radiology, 2008, 14, 127-30.	1.5	3
278	Secondary breast lymphoma diagnosed by vacuum-assisted breast biopsy: a case report. Journal of Medical Case Reports, 2007, 1, 113.	0.8	5
279	Bilateral synchronous breast carcinomas followed by a metastasis to the gallbladder: a case report. World Journal of Surgical Oncology, 2007, 5, 101.	1.9	21
280	Is zero underestimation feasible? Extended Vacuum-assisted breast biopsy in solid lesions – a blind study. World Journal of Surgical Oncology, 2007, 5, 53.	1.9	17
281	Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World Journal of Surgical Oncology, 2007, 5, 57.	1.9	41
282	Vacuum-assisted breast biopsy: The value and limitations of cores with microcalcifications. Pathology Research and Practice, 2007, 203, 563-566.	2.3	10
283	Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 893-897.	2.8	8
284	Vacuum-assisted breast biopsy: insight into stress-induced endocrine events. In Vivo, 2007, 21, 1081-4.	1.3	3
285	The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model. In Vivo, 2004, 18, 513-6.	1.3	8
286	Hormone Therapies. , 0, , 159-186.		0